Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives
The Hedgehog pathway (HhP) plays an important role in normal embryonic development and its abnormal function has been linked to a variety of neoplasms. Recently, the complex mechanisms involved in this pathway have been deciphered and the cross talks with other important pathways involved in carcino...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-02-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/8/2/153 |
| _version_ | 1797708845803372544 |
|---|---|
| author | Daniel Girardi Adriana Barrichello Gustavo Fernandes Allan Pereira |
| author_facet | Daniel Girardi Adriana Barrichello Gustavo Fernandes Allan Pereira |
| author_sort | Daniel Girardi |
| collection | DOAJ |
| description | The Hedgehog pathway (HhP) plays an important role in normal embryonic development and its abnormal function has been linked to a variety of neoplasms. Recently, the complex mechanisms involved in this pathway have been deciphered and the cross talks with other important pathways involved in carcinogenesis have been characterized. This knowledge has led to the development of targeted therapies against key components of HhP, which culminated in the approval of vismodegib for the treatment of advanced basal cell carcinoma in 2012. Since then, other compounds have been developed and evaluated in preclinical and clinical studies with interesting results. Today, several medications against components of the HhP have demonstrated clinical activity as monotherapies and in combination with cytotoxic treatment or other targeted therapies against mitogenic pathways that are linked to the HhP. This review aims to clarify the mechanism of the HhP and the complex crosstalk with others pathways involved in carcinogenesis and to discuss both the evidence associated with the growing number of medications and combined therapies addressing this pathway and future perspectives. |
| first_indexed | 2024-03-12T06:27:36Z |
| format | Article |
| id | doaj.art-fc629c13402d46428a7bfd6c66aee249 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T06:27:36Z |
| publishDate | 2019-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-fc629c13402d46428a7bfd6c66aee2492023-09-03T01:51:34ZengMDPI AGCells2073-44092019-02-018215310.3390/cells8020153cells8020153Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future PerspectivesDaniel Girardi0Adriana Barrichello1Gustavo Fernandes2Allan Pereira3Division of Medical Oncology, Hospital Sírio-Libanês, Brasilia 70200-730, BrazilDivision of Medical Oncology, Hospital Sírio-Libanês, Brasilia 70200-730, BrazilDivision of Medical Oncology, Hospital Sírio-Libanês, Brasilia 70200-730, BrazilDivision of Medical Oncology, Hospital Sírio-Libanês, Brasilia 70200-730, BrazilThe Hedgehog pathway (HhP) plays an important role in normal embryonic development and its abnormal function has been linked to a variety of neoplasms. Recently, the complex mechanisms involved in this pathway have been deciphered and the cross talks with other important pathways involved in carcinogenesis have been characterized. This knowledge has led to the development of targeted therapies against key components of HhP, which culminated in the approval of vismodegib for the treatment of advanced basal cell carcinoma in 2012. Since then, other compounds have been developed and evaluated in preclinical and clinical studies with interesting results. Today, several medications against components of the HhP have demonstrated clinical activity as monotherapies and in combination with cytotoxic treatment or other targeted therapies against mitogenic pathways that are linked to the HhP. This review aims to clarify the mechanism of the HhP and the complex crosstalk with others pathways involved in carcinogenesis and to discuss both the evidence associated with the growing number of medications and combined therapies addressing this pathway and future perspectives.https://www.mdpi.com/2073-4409/8/2/153Hedgehogtargeted therapySMO inhibitorGLI |
| spellingShingle | Daniel Girardi Adriana Barrichello Gustavo Fernandes Allan Pereira Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives Cells Hedgehog targeted therapy SMO inhibitor GLI |
| title | Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives |
| title_full | Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives |
| title_fullStr | Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives |
| title_full_unstemmed | Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives |
| title_short | Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives |
| title_sort | targeting the hedgehog pathway in cancer current evidence and future perspectives |
| topic | Hedgehog targeted therapy SMO inhibitor GLI |
| url | https://www.mdpi.com/2073-4409/8/2/153 |
| work_keys_str_mv | AT danielgirardi targetingthehedgehogpathwayincancercurrentevidenceandfutureperspectives AT adrianabarrichello targetingthehedgehogpathwayincancercurrentevidenceandfutureperspectives AT gustavofernandes targetingthehedgehogpathwayincancercurrentevidenceandfutureperspectives AT allanpereira targetingthehedgehogpathwayincancercurrentevidenceandfutureperspectives |